« Back
Home /
αGalCer-RBD

αGalCer-RBD

Item no.	HY-144120-100mg
Manufacturer	MedChem Express
Amount	100 mg
Category	Reagents & Chemicals Biochemicals
Type	Chemicals
Specific against	other
Citations	[1]Wang J, et al. Self-Adjuvanting Lipoprotein Conjugate αGalCer-RBD Induces Potent Immunity against SARS-CoV-2 and its Variants of Concern. J Med Chem. 2022;65(3):2558-2570.
Smiles	O[C@H]1[C@H]([C@H](O[C@@H]([C@@H]1O)OC[C@@H]([C@@H]([C@@H](CCCCCCCCCCCCCC)O)O)NC(C#CC#CC#CC#CC#CC#CC#CC#CC#CC#CC#CC#CC)=O)CNC(COCCOCCOCCNC(CON)=O)=O)O.[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH]
ECLASS 10.1	32160000
ECLASS 11.0	32160000
UNSPSC	12000000
Available
Product Description	αGalCer-RBD is a self-adjuvanting lipoprotein conjugate. αGalCer-RBD induces potent immunity against SARS-CoV-2 and its variants of concern. αGalCer-RBD conjugate induces RBD-specific, cytokine-producing T cell development. αGalCer-RBD has great potential to be an effective COVID-19 vaccine candidate. α-Galactosylceramide (αGalCer) is a potent invariant natural killer T cell (iNKT) agonist[1]. RBD: receptor-binding domain
Shipping	Room temperature
Manufacturers Applications	COVID-19-anti-virus
MolecularWeight	1119.60
Clinical_Information	No Development Reported
Manufacturers Research_Area	Infection
Solubility	10 mM in DMSO
Manufacturers Target	SARS-CoV
Pathway	Anti-infection
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 100 mg

available

Request delivery time